Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Ayala Pharmaceuticals Announces Presentation at the European Society for Medical Oncology (ESMO)

REHOVOT, Israel & WILMINGTON, Del.

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced that a poster will be presented at the European Society for Medical Oncology (ESMO), being held in Barcelona, Spain from September 27 to October 1, 2019.

Presentation information is as follows:

Title: ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notchact mut): preliminary safety and efficacy data 
Session Title: Poster Display Session 
Session Date and Time: Monday, September 30, 2019 at 12:00pm to 1:00pm CET 
Presentation Number: 1148P 
Location: Poster Area (Hall 4) 
Presenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala’s lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY). For more information, visit www.ayalapharma.com

Investors:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
Julie.seidel@sternir.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

Tags:




×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.